聚乙二醇化干扰素α-2b单药治疗及聚乙二醇化干扰素α-2b联合拉米夫定治疗乙肝病毒e抗原阴性慢性乙型肝炎患者
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
作者信息
Kaymakoglu Sabahattin, Oguz Dilek, Gur Gurden, Gurel Selim, Tankurt Ethem, Ersöz Galip, Ozenirler Seren, Kalayci Cem, Poturoglu Sule, Cakaloglu Yilmaz, Okten Atilla
机构信息
Istanbul University, Department of Gastroenterohepatology, Istanbul Medical Faculty, Capa, Istanbul, Turkey.
出版信息
Antimicrob Agents Chemother. 2007 Aug;51(8):3020-2. doi: 10.1128/AAC.00088-07. Epub 2007 May 21.
Abstract
Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.
摘要
48例乙型肝炎病毒（HBV）e抗原阴性的慢性乙型肝炎患者接受聚乙二醇化干扰素α-2b单药治疗或联合拉米夫定治疗48周，并随访额外24周。随访结束时，单药治疗组（24%）和联合治疗组（26%）的病毒学应答率（HBV DNA水平<400拷贝/ml）相似。
相似文献
1
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.聚乙二醇化干扰素α-2b单药治疗及聚乙二醇化干扰素α-2b联合拉米夫定治疗乙肝病毒e抗原阴性慢性乙型肝炎患者
Antimicrob Agents Chemother. 2007 Aug;51(8):3020-2. doi: 10.1128/AAC.00088-07. Epub 2007 May 21.
2
Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.拉米夫定与聚乙二醇化干扰素α-2b序贯联合疗法与拉米夫定单药疗法治疗HBeAg阴性慢性乙型肝炎的比较
J Gastroenterol Hepatol. 2007 Oct;22(10):1582-8. doi: 10.1111/j.1440-1746.2007.05103.x. Epub 2007 Aug 7.
3
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.聚乙二醇化干扰素α-2b单药或联合拉米夫定治疗HBeAg阳性慢性乙型肝炎：一项随机试验
Lancet. 2005;365(9454):123-9. doi: 10.1016/S0140-6736(05)17701-0.
4
5
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.聚乙二醇干扰素α-2a、拉米夫定及两者联合治疗HBeAg阳性慢性乙型肝炎
N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470.
6
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.聚乙二醇干扰素α-2a单药、拉米夫定单药以及二者联合用于HBeAg阴性慢性乙型肝炎患者。
N Engl J Med. 2004 Sep 16;351(12):1206-17. doi: 10.1056/NEJMoa040431.
7
8
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.聚乙二醇干扰素α-2a延长疗程治疗乙肝e抗原阴性慢性乙型肝炎的一项试点研究。
Am J Gastroenterol. 2007 Dec;102(12):2718-23. doi: 10.1111/j.1572-0241.2007.01449.x. Epub 2007 Jul 27.
9
Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B.
Scand J Gastroenterol. 2009;44(8):1021-2. doi: 10.1080/00365520902937370.
10
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.基于治疗过程中乙型肝炎表面抗原下降情况预测乙型肝炎 e 抗原阳性慢性乙型肝炎对聚乙二醇干扰素 alfa-2b 的持续应答。
Hepatology. 2010 Oct;52(4):1251-7. doi: 10.1002/hep.23844.
引用本文的文献
1
Dynamic Changes of Growth and Thyroid Function in Young Children With Chronic Hepatitis B Treated With Peginterferon Monotherapy.聚乙二醇干扰素单药治疗慢性乙型肝炎幼儿生长及甲状腺功能的动态变化
Pediatr Infect Dis J. 2025 Feb 1;44(2):112-117. doi: 10.1097/INF.0000000000004567. Epub 2024 Oct 1.
2
Systematic review and meta-analysis: combination of nucleos(t)ide analogs and pegylated interferon alpha versus pegylated interferon alpha monotherapy for the functional cure of chronic hepatitis B.系统评价与荟萃分析：核苷（酸）类似物与聚乙二醇化干扰素α联合用药对比聚乙二醇化干扰素α单药治疗慢性乙型肝炎功能性治愈的疗效
Front Pharmacol. 2024 Jul 5;15:1403805. doi: 10.3389/fphar.2024.1403805. eCollection 2024.
3
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.初治慢性乙型肝炎的抗病毒治疗：随机对照试验的系统评价和网络荟萃分析。
Syst Rev. 2019 Aug 19;8(1):207. doi: 10.1186/s13643-019-1126-1.
4
Alpha-interferon treatment in hepatitis B.α干扰素治疗乙型肝炎。
Ann Transl Med. 2017 Apr;5(7):159. doi: 10.21037/atm.2017.03.69.
5
A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.干扰素单药治疗或联合不同核苷（酸）类似物治疗慢性乙型肝炎疗效的Meta分析
Int J Environ Res Public Health. 2016 Jul 21;13(5):730. doi: 10.3390/ijerph13070730.
6
Interferon and nucleoside analog combination therapy for hepatitis B.干扰素与核苷类似物联合治疗乙型肝炎
Clin J Gastroenterol. 2010 Apr;3(2):69-72. doi: 10.1007/s12328-010-0135-3. Epub 2010 Feb 23.
7
Economic evaluation of treatments for chronic hepatitis B.慢性乙型肝炎治疗的经济学评价。
Braz J Infect Dis. 2013 Jul-Aug;17(4):418-26. doi: 10.1016/j.bjid.2012.12.005. Epub 2013 Jul 10.
8
Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.基于聚乙二醇干扰素α的慢性乙型肝炎治疗：聚焦于 HBsAg 清除或血清学转换的荟萃分析。
BMC Infect Dis. 2011 Jun 9;11:165. doi: 10.1186/1471-2334-11-165.
9
Combination treatment in HBeAg-negative chronic hepatitis B.HBeAg阴性慢性乙型肝炎的联合治疗
World J Hepatol. 2009 Oct 31;1(1):43-7. doi: 10.4254/wjh.v1.i1.43.
10
Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop.治疗慢性乙型肝炎的当前方法：何时开始，用什么开始，何时停止。
Hepatol Int. 2008 May;2(Supplement 1):19-27. doi: 10.1007/s12072-008-9059-0. Epub 2008 Mar 5.
本文引用的文献
1
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?慢性乙型肝炎病毒感染的抗病毒治疗——免疫调节还是病毒抑制？
Neth J Med. 2006 Jun;64(6):175-85.
2
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.法国慢性乙型肝炎患者的特征：HBe抗原阴性病例占主导频率。
J Hepatol. 2006 Sep;45(3):355-60. doi: 10.1016/j.jhep.2006.03.007. Epub 2006 Apr 18.
3
The current status of antiviral therapy of chronic hepatitis B.
J Clin Virol. 2005 Dec;34 Suppl 1:S115-24. doi: 10.1016/s1386-6532(05)80020-4.
4
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.聚乙二醇干扰素α-2a、拉米夫定及两者联合治疗HBeAg阳性慢性乙型肝炎
N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470.
5
Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.拉米夫定对比拉米夫定与干扰素联合治疗HBeAg（-）慢性乙型肝炎
J Viral Hepat. 2005 May;12(3):262-8. doi: 10.1111/j.1365-2893.2005.00566.x.
6
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.慢性乙型肝炎联合治疗的随机对照试验：聚乙二醇化干扰素α-2b与拉米夫定联合用药与单用拉米夫定的比较。
Ann Intern Med. 2005 Feb 15;142(4):240-50. doi: 10.7326/0003-4819-142-4-200502150-00006.
7
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.聚乙二醇化干扰素α-2b单药或联合拉米夫定治疗HBeAg阳性慢性乙型肝炎：一项随机试验
Lancet. 2005;365(9454):123-9. doi: 10.1016/S0140-6736(05)17701-0.
8
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.聚乙二醇干扰素α-2a单药、拉米夫定单药以及二者联合用于HBeAg阴性慢性乙型肝炎患者。
N Engl J Med. 2004 Sep 16;351(12):1206-17. doi: 10.1056/NEJMoa040431.
9
Treatment of chronic hepatitis B: current challenges and future directions.慢性乙型肝炎的治疗：当前挑战与未来方向
Rev Med Virol. 2003 Jul-Aug;13(4):255-72. doi: 10.1002/rmv.393.
10
Current state of interferon therapy in the treatment of chronic hepatitis B.
Semin Liver Dis. 2002;22 Suppl 1:7-13. doi: 10.1055/s-2002-35695.
Zotero 插件